

FILE COPY

SCULLY, SCOTT, MURPHY & PRESSER
400 GARDEN CITY PLAZA
GARDEN CITY, NEW YORK 11530

Telephone: (516) 742-4343

Facsimile: (516) 742-4366

E-Mail: intprop@ssmp.com

FACSIMILE TRANSMISSION

To: U. S. Patent and Trademark Office Attention: Corrected Filing Receipt

Date: February 19, 2002

Fax # 703-308-7751

Pages 5

From: SCULLY, SCOTT, MURPHY & PRESSER

Re: Tracy Willson, et al.

U.S. Patent Appln. No. 09/036,568

NOVEL HAEMOPOIETIN RECEPTOR AND

AND GENETIC SEQUENCES ENCODING SAME

Our Docket: 11373Z

COMMENTS:

The Filing Receipt for the above-identified patent application has information incorrect in the section of : Domestic priority data, and should read:

DOMESTIC PRIORITY DATA AS CLAIMED BY APPLICANT:

THIS APPLICATION IS A CON OF 09/051,843 10/23/1996

WHICH IS A 371 OF PCT/AU96/00668 10/23/1998

Please send to us a corrected Filing Receipt with the information as it is shown on the pages to follow.

Thank you.

If there are any problems concerning this facsimile, please call (516) 742-4343 and ask for Rosemarie at Ext.596.

CONFIDENTIALITY: The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right of publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/036,568	11/07/2001	1646	1020	11373Z	24	16	1

CONFIRMATION NO. 4029

FILING RECEIPT



OC00000007415793

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530

Date Mailed: 02/04/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Tracy Willson, North Balwyn, AUSTRALIA;
Nicos A. Nicola, Mont Albert, AUSTRALIA;
Douglas J. Hilton, Warrandyte, AUSTRALIA;
Donald Metcalf, Balwyn, AUSTRALIA;
Jian Guo Zhang, Hoppers Crossing, AUSTRALIA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/051,843 06/29/1998 *
WHICH IS A 371 OF PCT/AU96/00668 10/23/1996
(*) Data inconsistent with PTO records.

Foreign Applications

AUSTRALIA PN 6135 10/23/1995
AUSTRALIA PN 7276 12/22/1995
AUSTRALIA PO 2208 09/09/1996

If Required, Foreign Filing License Granted 02/01/2002

Projected Publication Date: 05/16/2002

Non-Publication Request: No

Early Publication Request: No

Title

Novel haemopoietin receptor and genetic sequences encoding same

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

COMBINED DECLARATION

FOR PATENT APPLICATION AND POWER

ATTORNEY

11373

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: "A novel haemopoietin receptor and genetic sequences encoding same"

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application

Serial No. _____

on 22 April 1998

and was amended

on _____

(if applicable).

☒ was filed as PCT international application

Number PCT/AU96/00668

on 23 October 1998

and was amended under PCT Article 19

on _____

(if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY of PCT applicant PCT No.	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Australia	PN 6135	23 October 1995	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Australia	PN 7276	22 December 1995	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Australia	PN 2208	9 September 1996	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

**VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE SPECIFICATION:**

Page 1, after the title, please insert the following:

--CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of application Serial Number

09/051,843 filed October 23, 1996.--

Page 1, line 5, insert the heading --FIELD OF THE INVENTION--;

Page 1, line 11, insert the heading

--BACKGROUND OF THE INVENTION--;

Page 3, line 9, insert the heading --SUMMARY OF THE INVENTION--;

Page 4, line 12, insert the heading --DETAILED DESCRIPTION OF THE
INVENTION--;

Please replace the heading beginning at Page 31, line 11 with the following new heading:

[In the Figures] BRIEF DESCRIPTION OF THE DRAWINGS:

IN THE CLAIMS:

Please cancel Claims 1-35 without prejudice, before calculating the filing fee of this
continuation application.

Please add the following new Claims:

36. (New) An isolated polypeptide which is capable of binding human IL-13
and/or human IL-4.

37. (New) The isolated polypeptide of Claim 36 comprising SEQ ID NO:4.

38. (New) The isolated polypeptide of Claim 37 comprising a derivative of
SEQ ID NO:4.